(RTTNews) - Acurx Pharmaceuticals, Inc. (ACXP) Monday announced that its lead antibiotic candidate, ibezapolstat, is advancing to international Phase 3 clinical trials for treating C. difficile Infection.

The results demonstrated that tagatose consumption not only proved safe for animals but also significantly reduced infection symptoms and severity

A group of gut bacteria successfully hindered recurrent Clostridium difficile infection in mice, offering alternative therapeutic strategies to antibiotics and fecal transplant.

A synthetic microbiome therapy, tested in mice, holds promise as a new treatment for C. difficile, a notoriously difficult-to-treat bacterial infection, according to a team of researchers at Penn State. The targeted treatment was as effective as human fecal transplants in mice against C. difficile infection with fewer safety concerns, protecting against severe symptoms and decreasing recurrent infections.

We report a comprehensive evaluation of the toxin B (TcdB) vaccine adjuvanted with a dual Toll-like receptor ligand liposome adjuvant for Clostridioides difficile infection (CDI). The vaccine completely protected mice from a lethal infection. Compared to alum adjuvanted TcdB, it generated functional …

Albany United States As per DelveInsight s assessment globally Clostridium Difficile Infections pipeline constitutes 20 key companies continuously working towards developing 22 Clostridium Difficile Infections treatment therapies analysis of Clinical Trials Therapies Mechanism of Action Route of Administration and Developments ...

Prevention beats treatment for everyone — patients, payers and investors.

Anti-IL5 therapy significantly reduces adverse events categorized as serious bacterial infections, pneumonia, influenza, non-serious lower respiratory tract infections and C.difficile infection. In the population of patients receiving anti-IL5 therapy, these effects may translate into substantial de …

Citrulline exerts anti-inflammatory effects in the intestines against C. difficile toxins and inhibits CDI recurrence in mice and hamsters.

EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused...

DelveInsight s Clostridium Difficile Infections Market Insights Epidemiology and Market Forecast 2034 report offers an in depth understanding of the Clostridium Difficile Infections historical and forecasted epidemiology as well as the Clostridium Difficile Infections market trends in the United States ...

A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C …

Lumen Bioscience's LMN-201 combines phage-derived endolysin with antibodies to accelerate C. diff cell death and prevent toxin-mediated damage.

Our report demonstrates for the first time the potential of Cwp2_A as an effective vaccine candidate against CDI in mice.

Pharmaceutical Innovations, Collaborative Research Initiatives, and Increased Awareness Driving Clostridium Difficile Infection Treatment Market Growth...

Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today annou

Las Vegas Nevada United States As per DelveInsight s assessment globally Clostridium Difficile Infections pipeline constitutes 20 key companies continuously working towards developing 22 Clostridium Difficile Infections treatment therapies analysis of Clinical Trials Therapies Mechanism of Action Route of Administration ...

Clostridium Difficile Infections companies working in market are Pfizer, Valneva, GlaxoSmithKline, Summit Therapeutics, MGB Biopharma, Acurx Pharmaceuticals.

Clostridium Difficile Infections companies working in market are Pfizer, Valneva, GlaxoSmithKline, Summit Therapeutics, MGB Biopharma, Acurx Pharmaceuticals.

spaniClostridioides difficile/i spores are essential for initiation, recurrence and transmission of the disease. The spore surface layers are composed of an outermost exosporium layer that surrounds another proteinaceous layer, the spore coat. These spore surfaces layers are responsible for initial/span …

Donor-derived fecal microbiota treatments are efficacious in preventing recurrent Clostridioides difficile infection (rCDI), but they have inherently variable quality attributes, are difficult to scale and harbor the risk of pathogen transfer. In contrast, VE303 is a defined consortium of eight puri …

Diarrhea associated with enteric infections, gut inflammation, and genetic defects poses a major health burden and results in significant morbidity and mortality. Impaired fluid and electrolyte absorption and/or secretion in the intestine are the hallmark of diarrhea. Electroneutral NaCl absorption …

Clostridioides difficile is the leading cause of healthcare- and antibiotic-associated diarrhea. Surface layer protein A (SlpA), an essential component of the bacterium's outermost layer, contributes to colonization and inflammation. The peroxisome proliferator-activated receptor gamma (PPAR-γ) has …

Clostridioides difficile (C. difficile) infection (CDI) is a life-threatening healthcare-associated infection occurring worldwide. C. difficile toxins (toxin A and toxin B) are the major virulence factors, causing CDI-related diarrhea and complications. Recent studies have shown that sulfated glycos …

Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce weight loss, but LPOXY Therapeutics has penned a

Background: Clostridioides difficile (C. difficile) infection (CDI) is the primary cause of antibioticassociated diarrhea. Due to its high resistance rate to...

/PRNewswire/ -- LPOXY Therapeutics, Inc. ("LPOXY"), a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease...

Nature Medicine - Results of multi-omic profiling of the microbiome and host immunity of individuals treated with VE303 to prevent recurrent Clostridioides difficile infection in the context of a...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in Phase 2. Data expected in 2025.